Rosacea News and Research

Latest Rosacea News and Research

Vicept completes $16 million Series A financing

Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences.

30 Jun 2010

Quick-Med Technologies receives Notice of Allowance for MultiStat family of compounds

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for intellectual property that extends the current patent coverage for the Company's MultiStat family of compounds. The forthcoming patent is part of a portfolio that Quick-Med has licensed from the University of Michigan.

18 Jun 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

Helix BioMedix reports revenue of approximately $391,000 in 2009

Helix BioMedix, Inc., a developer of bioactive peptides, announced financial results for the year ended December 31, 2009.

26 Mar 2010

Galderma Laboratories' Differin Lotion receives FDA approval

Galderma Laboratories, L.P. today announced the U.S. Food and Drug Administration approval of Differin® (adapalene) Lotion, 0.1%, the first-ever lotion formulation of the well-tolerated retinoid adapalene, for the treatment of acne. Differin Lotion, 0.1% will be available by prescription in April 2010.

22 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

freshHAIR: A new hair care line to prevent acne

Renee Cobos, MD, a board certified dermatologist and associate professor of dermatology at the University of California, Irvine, announced the launch of RC freshHAIR™, the first dermatologist-created hair care line that is specifically formulated to treat and prevent acne, acne rosacea, seborrhea (dandruff) and oily skin. RC freshHAIR is the newest addition to the RC Dermatology™ line of skin care products.

18 Jan 2010

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

PhotoMedex and Galderma Laboratories, L.P. have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (“AK”).

11 Jan 2010

ZO Skin Health files complaint against Obagi Medical Products

Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today announced that it was served January 7, 2010 with a complaint from ZO Skin Health, Inc., a company affiliated with Dr. Zein Obagi, OMP’s original founder.

9 Jan 2010

Revance Therapeutics closes $35 million Series D financing

Revance Therapeutics, Inc. (“Revance”) today announced the first $25 million closing of a $35 million Series D financing. The round was led by Essex Woodlands Health Ventures Fund VIII.

4 Jan 2010

CDA launches Acne And Rosacea Awareness Campaigns

The temperature drop outside is leaving many Canadians red in the face but dermatologists say the culprit could be acne or rosacea. The Canadian Dermatology Association (CDA) is launching Acne and Rosacea Awareness Campaigns to give sufferers the advice they need to cope with these diseases.

8 Dec 2009

New study reveals certain prescription drugs can be harmful to fetus

More than six percent of expectant mothers in Quebec consume prescription drugs that are known to be harmful to their fetuses, according to a Universit- de Montr-al investigation published in the British Journal of Obstetrics and Gynaecology

18 Nov 2009

FDA accepts Sol-Gel’s Investigational New Drug Application for DER45-EV Gel

Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.

11 Nov 2009

Tips for treating age-related dermatologic concerns

Everyone expects their bodies to change as they get older. From wrinkles and sagging skin to brittle bones and aches and pains, the aging process is inevitable. In addition, there are a number of medical dermatologic conditions that surface with age that can cause people even more stress. Fortunately, dermatologists can help diagnose and treat these conditions no matter when they strike.

11 Nov 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

Premier Plastic Surgery redesigns its website to provide more information of cosmetic surgery

Premier Plastic Surgery of Kansas City, serving residents of Kansas City and beyond for 22 years, has redesigned its extensive website to include a separate section on Cosmetic Surgery for Males, a new Skin Care Centre, and a Plastic Surgery Blog that features breaking news on emerging research, techniques and products.

19 Oct 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

940nm wavelength laser is superior for treating facial spider veins: BUSM researchers

Researchers from Boston University School of Medicine (BUSM) have concluded that the 940nm wavelength laser is superior for treating facial spider veins (telangiectasias) as compared to the 532nm wavelength laser. The findings, which appear in the recent issue of Lasers in Surgery and Medicine, are the first time these lasers were tested against each other for superiority.

7 Oct 2009

New consumer At-Home Skin Typing and Analysis Kit unveiled

Reveal Sciences, LLC, a cosmetics and aesthetics innovation company pioneering breakthrough skin care diagnostics, has announced the launch of the new consumer At-Home Skin Typing and Analysis Kit.

5 Oct 2009

Impax Laboratories challenges Galderma Laboratories' patents

Impax Laboratories, Inc. confirms that it has initiated a challenge of the patents listed by Galderma Laboratories, L.P. in connection with its ORACEA® (doxycycline) delayed-release capsules, 40 mg.

21 Sep 2009